Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
MAIN AIM: To compare the pharmacological potency of administering adjusted 600 mg clopidogrel
loading doses and 60 mg prasugrel in patients with high on-clopidogrel platelet reactivity
(HPR) after PCI.
SECONDARY OBJECTIVES: To define the optimal maintenance dose with both prasugrel (5 mg vs. 10
mg) and clopidogrel (75 mg vs. 150 mg) in patients with HPR for chronic therapy.
DESIGN: Prospective, Randomized, Open-label, Single-center trial.
PRIMARY ENDPOINT: Platelet reactivity measured with Multiplate between clopidogrel and
prasugrel arm at day 4.